Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John L Reagan

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|February 19, 2014
Viral lymphomagenesis: from pathophysiology to the rationale for novel therapiesJorge J Castillo, John L Reagan, Kenneth D Bishop, et al.
American Journal of Hematology|December 19, 2019
Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphomaAdam J Olszewski, James N Butera, John L Reagan, et al.
British Journal of Haematology|January 24, 2015
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphomaJorge J Castillo, John L Reagan, William M Sikov, et al.
Blood|April 13, 2012
Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studiesJorge J Castillo, Nikhil Mull, John L Reagan, et al.
Leukemia & Lymphoma|March 30, 2017
Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?William M Rafelson, John L Reagan, Loren D Fast, et al.
Annals of Hematology|September 2, 2020
Antibiotic use during cytarabine consolidation in acute myeloid leukemiaColin A Vale, Pamela C Egan, Randall Ingham, et al.
Blood|October 24, 2002
Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantationGudrun Ratzinger, John L Reagan, Glenn Heller, et al.
Thrombosis Research|September 27, 2020
Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumoniaAndrew Hsu, Yuchen Liu, Adam S Zayac, et al.
Leukemia & Lymphoma|September 11, 2020
Adjuvant chemotherapy administration and survival outcomes of lymphoma survivors with common solid tumors: a population-based study†Mengyang Di, Orestis A Panagiotou, John L Reagan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 4, 2021
Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemiaAri Pelcovits, Jozal Moore, Brianna Bakow, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|February 19, 2014
Viral lymphomagenesis: from pathophysiology to the rationale for novel therapiesJorge J Castillo, John L Reagan, Kenneth D Bishop, et al.
American Journal of Hematology|December 19, 2019
Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphomaAdam J Olszewski, James N Butera, John L Reagan, et al.
British Journal of Haematology|January 24, 2015
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphomaJorge J Castillo, John L Reagan, William M Sikov, et al.
Blood|April 13, 2012
Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studiesJorge J Castillo, Nikhil Mull, John L Reagan, et al.
Leukemia & Lymphoma|March 30, 2017
Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?William M Rafelson, John L Reagan, Loren D Fast, et al.
Annals of Hematology|September 2, 2020
Antibiotic use during cytarabine consolidation in acute myeloid leukemiaColin A Vale, Pamela C Egan, Randall Ingham, et al.
Blood|October 24, 2002
Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantationGudrun Ratzinger, John L Reagan, Glenn Heller, et al.
Thrombosis Research|September 27, 2020
Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumoniaAndrew Hsu, Yuchen Liu, Adam S Zayac, et al.
Leukemia & Lymphoma|September 11, 2020
Adjuvant chemotherapy administration and survival outcomes of lymphoma survivors with common solid tumors: a population-based study†Mengyang Di, Orestis A Panagiotou, John L Reagan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 4, 2021
Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemiaAri Pelcovits, Jozal Moore, Brianna Bakow, et al.
Pageof 8